Mallinckrodt PLC Company Profile (NYSE:MNK)

About Mallinckrodt PLC

Mallinckrodt PLC logoMallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company's segments include Specialty Brands, Specialty Generics and Nuclear Imaging. Its Specialty Brands segment produces and markets branded pharmaceutical and biopharmaceutical products for autoimmune and rare diseases; immunotherapy and neonatal respiratory critical care therapies, and central nervous system drugs. Its Specialty Generics segment produces specialty generic pharmaceuticals and active pharmaceutical ingredients (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its Nuclear Imaging segment manufactures and markets radiopharmaceuticals (nuclear medicine).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: MNK
  • CUSIP:
Key Metrics:
  • Previous Close: $76.31
  • 50 Day Moving Average: $76.94
  • 200 Day Moving Average: $65.86
  • 52-Week Range: $107,713,000.00 - $50.90
  • Trailing P/E Ratio: 14.39
  • Foreward P/E Ratio: 9.18
  • P/E Growth: 1.10
  • Market Cap: $8.22B
  • Outstanding Shares: 107,713,000
  • Beta: 1.52
  • Net Margins: 16.39%
  • Return on Equity: 17.78%
  • Return on Assets: 5.77%
  • Debt-to-Equity Ratio: 1.21%
  • Current Ratio: 1.68%
  • Quick Ratio: 1.31%
Additional Links:
Companies Related to Mallinckrodt PLC:

Analyst Ratings

Consensus Ratings for Mallinckrodt PLC (NYSE:MNK) (?)
Ratings Breakdown: 3 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $95.75 (25.48% upside)

Analysts' Ratings History for Mallinckrodt PLC (NYSE:MNK)
DateFirmActionRatingPrice TargetDetails
9/21/2016Morgan StanleyReiterated RatingBuy$82.00View Rating Details
9/16/2016Leerink SwannReiterated RatingOutperform$91.00 -> $92.00View Rating Details
9/7/2016Piper Jaffray Cos.Reiterated RatingOverweight$112.00 -> $105.00View Rating Details
8/31/2016Deutsche Bank AGLower Price TargetBuy$87.00 -> $84.00View Rating Details
8/29/2016MizuhoReiterated RatingBuy$91.00View Rating Details
8/26/2016Goldman Sachs Group Inc.Reiterated RatingNeutral$83.00View Rating Details
8/25/2016BMO Capital MarketsReiterated RatingPositive -> Outperform$93.00View Rating Details
8/25/2016Barclays PLCReiterated RatingOverweight$88.00View Rating Details
8/12/2016Stifel NicolausInitiated CoverageBuy$95.00View Rating Details
8/4/2016Jefferies GroupReiterated RatingBuy$85.00 -> $95.00View Rating Details
8/3/2016JPMorgan Chase & Co.Set Price TargetHold$85.00View Rating Details
8/3/2016GuggenheimReiterated RatingBuy$98.00View Rating Details
6/10/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
5/4/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details
3/16/2016Northland SecuritiesReiterated RatingBuy$95.00View Rating Details
2/2/2016NomuraReiterated RatingNeutral$100.00View Rating Details
10/7/2015Bank of America Corp.Lower Price TargetBuy$135.00 -> $131.00View Rating Details
1/30/2015CRT CapitalBoost Price TargetFairly Valued$84.00 -> $97.00View Rating Details
10/1/2014Buckingham ResearchBoost Price TargetBuy$107.00 -> $115.00View Rating Details
(Data available from 9/26/2014 forward)


Earnings History for Mallinckrodt PLC (NYSE:MNK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2016Q316$2.00$2.20$920.35 million$970.60 millionViewListenView Earnings Details
5/3/2016Q216$1.72$2.01$878.70 million$918.00 millionViewListenView Earnings Details
2/2/2016Q116$1.77$2.00$888.33 million$915.00 millionViewListenView Earnings Details
11/23/2015Q415$1.77$1.84$869.41 million$882.40 millionViewListenView Earnings Details
8/4/2015Q315$1.82$2.05$983.81 million$965.10 millionViewListenView Earnings Details
5/5/2015Q215$1.48$1.72$860.89 million$909.90 millionViewListenView Earnings Details
2/3/2015Q115$1.55$1.84$880.12 million$866.00 millionViewListenView Earnings Details
11/19/2014Q414$1.41$1.68$759.04 million$789.00 millionViewListenView Earnings Details
8/7/2014Q314$0.87$1.20$278.80 million$653.10 millionViewListenView Earnings Details
5/8/2014Q214$0.78$0.95$566.50 million$557.80 millionViewListenView Earnings Details
2/6/2014Q1$0.66$0.88$539.24 million$540.20 millionViewListenView Earnings Details
11/7/2013$0.85$1.02$572.57 million$552.20 millionViewListenView Earnings Details
8/9/2013Q3 2013$0.78$0.49$557.22 million$570.00 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mallinckrodt PLC (NYSE:MNK)
Current Year EPS Consensus Estimate: $7.67 EPS
Next Year EPS Consensus Estimate: $8.31 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 201610$1.64$1.87$1.77
Q2 20169$1.95$2.09$2.05
Q3 20163$1.98$2.14$2.04
Q4 20163$2.13$2.19$2.16
Q1 20171$1.99$1.99$1.99
Q2 20171$2.16$2.16$2.16
Q3 20171$2.02$2.02$2.02
Q4 20171$2.07$2.07$2.07
(Data provided by Zacks Investment Research)


Dividend History for Mallinckrodt PLC (NYSE:MNK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Mallinckrodt PLC (NYSE:MNK)
Insider Ownership Percentage: 0.53%
Institutional Ownership Percentage: 94.74%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/10/2016Hugh M O'neillVPBuy1,653$60.99$100,816.47View SEC Filing  
5/10/2016Matthew K HarbaughCFOBuy500$59.37$29,685.00View SEC Filing  
5/6/2016Mark TrudeauCEOBuy1,000$56.02$56,020.00View SEC Filing  
5/6/2016Steven J RomanoVPBuy900$56.00$50,400.00View SEC Filing  
3/4/2016Coleman N Lannum IIIVPBuy2,600$62.63$162,838.00View SEC Filing  
2/26/2016Meredith B FischerVPBuy1,400$69.80$97,720.00View SEC Filing  
2/12/2016Coleman N Lannum IIIVPBuy600$59.66$35,796.00View SEC Filing  
2/10/2016Coleman N Lannum IIIVPBuy1,300$62.58$81,354.00View SEC Filing  
2/9/2016Matthew K. HarbaughCFOBuy1,300$63.00$81,900.00View SEC Filing  
2/8/2016Coleman N. Lannum IIIVPBuy800$66.37$53,096.00View SEC Filing  
12/22/2015Coleman N Lannum IIISVPBuy500$72.50$36,250.00View SEC Filing  
12/11/2015Terrance L CarlsonGeneral CounselBuy1,000$69.10$69,100.00View SEC Filing  
12/2/2015Gary M. PhillipsVPBuy1,000$72.17$72,170.00View SEC Filing  
11/30/2015Mark TrudeauCEOBuy1,350$65.89$88,951.50View SEC Filing  
11/27/2015Coleman N Lannum IIISVPBuy1,200$66.86$80,232.00View SEC Filing  
11/27/2015Meredith B FischerVPBuy2,200$66.93$147,246.00View SEC Filing  
11/27/2015Terrance L CarlsonGeneral CounselBuy1,000$66.54$66,540.00View SEC Filing  
8/25/2015Hugh M O'neillSVPBuy1,197$83.52$99,973.44View SEC Filing  
8/25/2015Mark TrudeauCEOBuy1,000$83.08$83,080.00View SEC Filing  
8/21/2015Coleman N Lannum IIISVPBuy2,375$88.52$210,235.00View SEC Filing  
8/21/2015Mark TrudeauCEOBuy2,000$88.45$176,900.00View SEC Filing  
6/4/2015Coleman N Lannum IIIVPBuy1,300$126.41$164,333.00View SEC Filing  
6/2/2015Matthew K HarbaughCFOSell22,106$128.64$2,843,715.84View SEC Filing  
5/18/2015Mario D SaltarelliVPSell4,580$127.44$583,675.20View SEC Filing  
5/13/2015Don M BaileyDirectorSell51,417$122.45$6,296,011.65View SEC Filing  
5/11/2015Sandra L HattenVPSell2,024$122.29$247,514.96View SEC Filing  
4/13/2015Don M BaileyDirectorSell40,000$127.61$5,104,400.00View SEC Filing  
3/13/2015Don M BaileyDirectorSell40,000$123.40$4,936,000.00View SEC Filing  
2/13/2015Don M BaileyDirectorSell33,891$114.63$3,884,925.33View SEC Filing  
2/2/2015Mark TrudeauCEOSell11,925$105.94$1,263,334.50View SEC Filing  
1/9/2015Mark TrudeauCEOSell15,720$102.00$1,603,440.00View SEC Filing  
12/22/2014Peter G EdwardsVPSell1,265$99.69$126,107.85View SEC Filing  
12/18/2014Mark TrudeauCEOSell13,831$93.59$1,294,443.29View SEC Filing  
9/10/2014Raymond J FureyVPSell5,441$85.90$467,381.90View SEC Filing  
9/8/2014Don M BaileyDirectorSell221,177$85.23$18,850,915.71View SEC Filing  
9/5/2014Raymond J FureyVPSell15,000$85.47$1,282,050.00View SEC Filing  
9/5/2014Virgil D ThompsonDirectorSell25,000$83.76$2,094,000.00View SEC Filing  
9/2/2014Raymond J FureyVPSell10,303$81.61$840,827.83View SEC Filing  
8/29/2014Raymond J FureyVPSell4,840$80.90$391,556.00View SEC Filing  
8/19/2014Joseph A ZaccagninoDirectorBuy3,000$71.06$213,180.00View SEC Filing  
8/13/2014Paulson & Co IncMajor ShareholderBuy132,100$69.80$9,220,580.00View SEC Filing  
8/12/2014J Martin CarrollDirectorBuy2,000$69.24$138,480.00View SEC Filing  
8/12/2014Paulson & Co IncMajor ShareholderBuy467,900$68.78$32,182,162.00View SEC Filing  
8/11/2014Paulson & Co IncMajor ShareholderBuy207,900$69.70$14,490,630.00View SEC Filing  
8/7/2014Paulson & Co IncMajor ShareholderBuy700,200$70.15$49,119,030.00View SEC Filing  
8/1/2014Paulson & Co IncMajor ShareholderBuy275,000$69.60$19,140,000.00View SEC Filing  
6/11/2014Melvin D BoothDirectorBuy4,000$76.05$304,200.00View SEC Filing  
5/9/2014Paulson & Co Incmajor shareholderBuy786,207$73.63$57,888,421.41View SEC Filing  
2/3/2014Mark TrudeauCEOSell14,890$56.12$835,626.80View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Mallinckrodt PLC (NYSE:MNK)
DateHeadline logoMallinckrodt plc (NYSE:MNK) Ratings in Focus | Stocks Daily - Stocks Daily (NYSE:MNK) - September 24 at 10:37 AM logoMallinckrodt plc (NYSE:MNK) Ratings in Focus (NYSE:MNK) - September 23 at 5:48 PM logoEndo Int'l: New CEO "Has His Work Cut Out For Him" (NYSE:MNK) - September 23 at 5:48 PM
News IconEarnings According to Analysts for Mallinckrodt plc (NYSE:MNK)? - Frisco Fastball (NYSE:MNK) - September 23 at 10:53 AM logoMallinckrodt rebuffs Praxair's challenge of INOMAX patents - Seeking Alpha (NYSE:MNK) - September 23 at 10:53 AM logoValidity of Mallinckrodt's INOMAX® Patent Claims Upheld (NYSE:MNK) - September 23 at 10:53 AM logoCommit To Buy Mallinckrodt At $45, Earn 12.2% Using Options (NYSE:MNK) - September 21 at 10:19 AM logoMallinckrodt plc (NYSE:MNK)’s Accounts Payable Is $125.4 (NYSE:MNK) - September 21 at 10:19 AM logoHow Will Valeant’s Profitability Pan Out over the Long Term? (NYSE:MNK) - September 20 at 11:22 AM logoMallinckrodt Grows Investment in Dublin College Business and Technology Park Site to €85 million (NYSE:MNK) - September 19 at 10:43 AM logoMallinckrodt plc (NYSE:MNK) Price Forecast At $94.25 (NYSE:MNK) - September 18 at 10:33 AM logoMallinckrodt plc (NYSE:MNK) Price Forecast At $94.25 - Stocks Daily (NYSE:MNK) - September 17 at 5:49 PM logoLeerink Boosts PT on Mallinckrodt (MNK) to $92; Lifts INOMax Expectations (NYSE:MNK) - September 16 at 8:59 AM
News IconMallinckrodt plc (NYSE:MNK): How Are Analysts Advising to Play This Stock? - Post News (NYSE:MNK) - September 14 at 6:17 PM logoMallinckrodt plc (NYSE:MNK) Is Expected To Post EPS Of $2.19 (NYSE:MNK) - September 13 at 11:01 AM logoMallinckrodt To Present At Morgan Stanley Global Conference; Webcast At 8:45 AM (NYSE:MNK) - September 12 at 5:57 PM
News IconAnalysts Place Mallinckrodt plc (NYSE:MNK) Under the Lens of the Microscope - Post News (NYSE:MNK) - September 12 at 10:51 AM
News IconHC Trending Hot Stocks= CIGNA Corporation (CI), Mallinckrodt PLC (NYSE:MNK) - share market updates (press release) (NYSE:MNK) - September 12 at 10:51 AM
News IconThe Sell-side Consensus is in on Mallinckrodt plc (NYSE:MNK); Earnings & Target Updates - National Daily Press (NYSE:MNK) - September 9 at 5:55 PM
News IconThe Sell-side Consensus is in on Mallinckrodt plc (NYSE:MNK); Earnings & Target Updates (NYSE:MNK) - September 9 at 10:53 AM logoMallinckrodt (MNK) PT, Estimates Updated at Piper Jaffray Following Sale of Nuclear Business (NYSE:MNK) - September 7 at 9:45 AM logoMallinckrodt plc (NYSE:MNK) Is Expected To Post EPS Of $2.23 - (NYSE:MNK) - September 6 at 6:17 PM logoClinton Drug Plan No Threat to Innovators (NYSE:MNK) - September 6 at 6:17 PM logoMallinckrodt plc (NYSE:MNK) Is Expected To Post EPS Of $2.23 (NYSE:MNK) - September 4 at 5:36 PM
News IconWhat Do Analysts Think Of Mallinckrodt Plc (NYSE:MNK)? (NYSE:MNK) - September 1 at 9:19 AM logoMallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products (NYSE:MNK) - September 1 at 9:19 AM logoHealth Economic Data Following Orthopedic Surgery for OFIRMEV® (Acetaminophen) Injection Published in Advances in Therapy (NYSE:MNK) - September 1 at 9:19 AM logoMallinckrodt completes purchase of regenerative medicine company (NYSE:MNK) - September 1 at 9:19 AM logoMallinckrodt (MNK) Stock Price Target Reduced at Deutsche Bank (NYSE:MNK) - August 31 at 11:05 AM logoWhat’s behind Mallinckrodt’s Stratatech Acquisition? (NYSE:MNK) - August 30 at 6:11 PM logoHow StrataGraft Could Benefit Mallinckrodt’s Hospital Portfolio (NYSE:MNK) - August 30 at 6:11 PM
News IconMallinckrodt PLC Valuation – August 2016 $MNK (NYSE:MNK) - August 30 at 9:33 AM
News IconRatings & Crowd Appeal on Mallinckrodt plc (NYSE:MNK) - Post News (NYSE:MNK) - August 29 at 10:46 AM
News IconMallinckrodt PLC (NYSE:MNK), UnitedHealth Group Inc (NYSE:UNH) - NYSE Journal (press release) (NYSE:MNK) - August 26 at 5:59 PM logoShort Interest Drops 21.8% For MNK (NYSE:MNK) - August 25 at 6:10 PM logoMallinckrodt's Top Drug Could Go the Way of EpiPen (NYSE:MNK) - August 25 at 11:20 AM logoMallinckrodt Could Be Next in Spotlight Thanks to EpiPen Scrutiny (NYSE:MNK) - August 25 at 11:20 AM logoPiper Jaffray Stays Bullish on Mallinckrodt (MNK), Lifts PT to $112 (NYSE:MNK) - August 24 at 9:20 AM logoMALLINCKRODT PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial (NYSE:MNK) - August 24 at 9:20 AM logoMallinckrodt sells nuclear imaging business for $690 million (NYSE:MNK) - August 24 at 9:20 AM logoMallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million (NYSE:MNK) - August 24 at 9:20 AM logoMallinckrodt to sell nuclear imaging business for $690 million (NYSE:MNK) - August 24 at 9:20 AM logo[$$] Mallinckrodt to Sell Nuclear-Imaging Operations (NYSE:MNK) - August 24 at 9:20 AM logoExtracorporeal Photopheresis (ECP), Including Mallinckrodt's THERAKOS® ECP Immunomodulation, Receives … (NYSE:MNK) - August 23 at 10:39 AM logoMallinckrodt Says Switzerland Okays ECP For Reimbursement (NYSE:MNK) - August 23 at 10:39 AM logoExtracorporeal Photopheresis (ECP), Including Mallinckrodt's THERAKOS® ECP Immunomodulation, Receives Approval for Reimbursement by Swiss Federal Department of Home Affairs (NYSE:MNK) - August 23 at 10:39 AM logoMallinckrodt To Present At Morgan Stanley Global Healthcare Conference (NYSE:MNK) - August 22 at 10:48 AM logoAnalysts See Mallinckrodt plc (NYSE:MNK) Reporting EPS Of $2.32 (NYSE:MNK) - August 21 at 5:36 PM logoMallinckrodt To Present At Wells Fargo Securities Healthcare Conference (NYSE:MNK) - August 19 at 9:16 AM logoBehind Horizon’s Price-to-Sales Valuation (NYSE:MNK) - August 18 at 6:22 PM


Mallinckrodt PLC (NYSE:MNK) Chart for Monday, September, 26, 2016

Last Updated on 9/26/2016 by Staff